Biotechnology Company Investment Opportunity in Brussels, Belgium

- An AI-enhanced physics-based drug discovery company.
- Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads.
- Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates.
- The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma.
- The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model.
- Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's.
- The business is not yet profitable as it is reinvesting its revenue into research and development activities,
- The company has 2 additional contract employees for R&D activities.